Definitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience

Basit Öğe Kaydı
dc.authorid0000-0003-1493-8385
dc.contributor.authorYılmaz, Ufuk
dc.contributor.authorYılmaz, Ülkü
dc.contributor.authorYaşar, Zehra
dc.contributor.authorKıraklı, Esra Korkmaz
dc.contributor.authorÜlger, Şükran
dc.date.accessioned2021-06-23T19:44:28Z
dc.date.available2021-06-23T19:44:28Z
dc.date.issued2016
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractAim: Concurrent chemoradiotherapy (CRT) is the standard therapy for patients with unresectable Stage III nonsmall cell lung cancer (NSCLC). The aim of this study was to assess the efficacy and safety of concurrent CRT in unresectable Stage III NSCLC in Turkey. Patients and Methods: The study included 82 patients with histologically proven unresectable Stage III NSCLC, Eastern Cooperative Oncology Group performance status 0-1, who received concurrent CRT in two different referral centers. Treatment consisted of two cycles of cisplatin at 50 mg/m(2) on days 1, 8, 29, and 36 and etoposide 50 mg/m(2) between days 1 and 5, 29-33 and concurrent radiotherapy administered once daily, 1.8-2.0 Gy per fraction, at a total dose of 60-66 Gy. Results: The stages of the patients were Stage IIIA in 39 (47.5%) and IIIB in 43 (52.5%) patients. Complete and partial responses were achieved in 15 (18.2%) and 31 (37.8%) of the patients, respectively. Twenty-eight (34.2%) patients had stable disease and 8 (9.8) had progressive disease. Forty-one (50%) patients recurred during follow-up. The primary site of recurrence was as distant metastasis in 19 (23.2%) patients. Median overall survival (OS) was 20 months (95% confidence interval; 12.9-27.09 months), 3 and 4 years survivals were 27.9% and 20.9%, respectively. Median progression-free survival (PFS) was 9 months, 3 and 4 years PFSs were 20.1% and 16.1%. Myelosuppression was the most common toxicity. In 15 (19.2%) patients grade 2-3 lung toxicity and in seven (8.5%) patients' grade 2-3 dysphagia were reported. Conclusion: Concurrent CRT with cisplatin and etoposide schedule is a well-tolerated regimen with acceptable toxicity profile and survival rates in patients with unresectable Stage IIIA/IIIB NSCLC. Median survival and OS results were consistent with the literature.en_US
dc.identifier.doi10.4103/0973-1482.163682
dc.identifier.endpage339en_US
dc.identifier.issn0973-1482
dc.identifier.issn1998-4138
dc.identifier.issue1en_US
dc.identifier.pmid27072260en_US
dc.identifier.scopus2-s2.0-84966600157en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage334en_US
dc.identifier.urihttps://doi.org/10.4103/0973-1482.163682
dc.identifier.urihttps://hdl.handle.net/20.500.12491/8989
dc.identifier.volume12en_US
dc.identifier.wosWOS:000378176100060en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorYaşar, Zehra
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofJournal Of Cancer Research And Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectConcurrent Chemoradiotherapyen_US
dc.subjectNonsmall Cell Lung Canceren_US
dc.subjectStage IIIen_US
dc.subjectSurvivalen_US
dc.titleDefinitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experienceen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
ufuk-yilmaz.pdf
Boyut:
777.47 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu